Ina Research Incorporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Ina Research Incorporation with three other
pharmaceutical manufacturers in Asia:
China Regenerative Medicine International Ltd
of Hong Kong
sales of 356.99 million Hong Kong Dollars [US$45.73 million]
Hester Pharmaceuticals Limited
(1.23 billion Indian Rupees [US$19.11 million]
of which 88%
was Poultry Vaccines), and
(2.48 billion Japanese Yen [US$22.35 million]
of which 63%
was Health Inspection Equipment).
Ina Research Incorporation reported sales of ¥2.30 billion (US$20.66 million)
March of 2017.
increase of 8.5%
versus 2016, when the company's sales were ¥2.12 billion.
Despite this increase, sales are still
below the level achieved in 2015, when Ina Research Incorporation
reported sales of ¥2.99 billion.
Sales of Non-Clinical Business saw an increase
that was more than double the company's growth rate: sales were up
17.2% in 2017, from
¥1.68 billion to ¥1.97 billion.
Not all segments of Ina Research Incorporation experienced an increase in sales in 2017:
sales of Clinical Trial Business fell 90.9% to ¥13.57 million.